Clinical trial · Interventional
Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers
Phase II Study of Mild Whole Body Hyperthermia Combined With 5-Fluorouracil/Interferon-a/Liposomal Doxorubicin in Patients With Advanced Malignancy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Thermal therapy (hyperthermia of heat) can increase the effect of chemotherapy treatments. By itself, thermal therapy can also kill cancer cells. By using thermal therapy to treat the whole body, the investigators can treat cancer cells wherever they are throughout the entire body. In this study, the investigators are testing the combination of thermal therapy combined with chemotherapy to see: 1. if it improves the effect of the chemotherapy drugs, 2. if it helps the body fight the cancer cells, and 3. if this treatment is safe for the patient. This study does not offer heat treatment alone. Any patient with advanced or metastatic breast, or endometrial cancer resistant to standard treatment may be treated with the phase II protocol therapy; however, the patient will need to undergo some medical tests to make sure this treatment would be safe for them.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Cervix Neoplasms | Cervical Neoplasm | ALIAS | 0.90 |
| Endometrial Neoplasms | Endometrial Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Ovarian Neoplasms | Ovarian Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- 1
- description
- thermochemotherapy using fever-range whole-body thermal therapy combined with continuous infusion 5-fluorouracil, Doxil, and low-dose interferon-alpha.
- interventionNames
- Other: thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)
Primary outcomes (2)
- measure
- Tumor response
- timeFrame
- 5 years
- measure
- Response duration
- timeFrame
- 5 years
Secondary outcomes (1)
- measure
- Toxicity
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Resistant breast, endometrial, cervix, or ovarian cancer * No active metastasis to the brain * No more than 8 previous regimes of Doxil * Successful completion of preliminary function tests * Good ECOG score Exclusion Criteria: * Active metastasis to the brain * 8 or more previous cycles of Doxil * Poor completion of preliminary function tests * Poor ECOG score
References
Publications (0)
Data not yet available